PulmonxLUNG -2.26%49 Days Payable is 74.12 as of Mar. 2026, which is 41% above its 10-year median of 52.50. GuruFocus rates LUNG with a GF Score™ of 49/100 and a GF Value™ of $7.13 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Pulmonx ranks better than 58.24% on this metric.
Pulmonx's average Accounts Payable for the
three
months ended in Mar. 2026 was $3.69 Mil. Pulmonx's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $4.54 Mil.
Hence, Pulmonx's Days Payable for the
three
months ended in Mar. 2026 was 74.12.
The historical rank and industry rank for Pulmonx's Days Payable or its related term are showing as below:
LUNG'
s Days Payable Range Over the Past 10 Years
Min: 33.14 Med: 52.5 Max: 82.86
Current: 82.86
During the past 8 years, Pulmonx's highest Days Payable was 82.86. The lowest was 33.14. And the median was 52.50.
LUNG's Days Payable is ranked better than 58.24% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs LUNG: 82.86
Pulmonx's Days Payable
increased
from Mar. 2025 (59.70) to Mar. 2026 (74.12).
It may suggest that Pulmonxdelayed paying its suppliers.
Pulmonx Days Payable Related Terms
Pulmonx Days Payable Historical Data
* Premium members only.
The historical data trend for Pulmonx's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Pulmonx's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulmonx Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's Days Payable distribution charts can be found below:
* The bar in red indicates where Pulmonx's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pulmonx's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulmonx (LUNG) has a Days Payable of 74.12 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pulmonx and its competitors. This is 41% above median its historical median of 52.50. Over the past decade, Pulmonx's Days Payable has ranged from 33.14 to 82.86. According to the industry distribution chart, Pulmonx ranks #332 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 41.8%.
Is Pulmonx's Days Payable too high?
Pulmonx's current Days Payable of 74.12 is 41% above median its 10-year median of 52.50. Over the past 10 years, this metric has ranged from a low of 33.14 to a high of 82.86. The Medical Devices & Instruments industry median Days Payable is 68.07. Pulmonx's value of 74.12 is 8.9% above this industry median. Based on the distribution chart, Pulmonx ranks #332 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Pulmonx has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pulmonx's Days Payable compare to MDAI and QTI?
According to the Medical Devices & Instruments industry distribution chart, Pulmonx ranks #332 out of 795 companies for Days Payable. This puts Pulmonx in the upper half of its industry. The industry median Days Payable is 68.07. Pulmonx's value of 74.12 is 8.9% above this benchmark. Historically, Pulmonx's own Days Payable has ranged from 33.14 to 82.86 over the past decade. While the company's 10-year median is 52.50 vs. the industry median of 68.07, Pulmonx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulmonx's current Days Payable of 74.12 is 8.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pulmonx and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulmonx's current Days Payable is 74.12, which is 41% above median its own 10-year median of 52.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulmonx stock overvalued right now?
Based on GuruFocus' analysis, Pulmonx (LUNG) is currently considered Possible Value Trap. The stock's GF Value™ is $7.13, compared to a current price of $1.30 — trading 81.8% below its estimated fair value. The current Days Payable is 74.12, which is 41% above median its 10-year median of 52.50 and 8.9% above the Medical Devices & Instruments industry median of 68.07. Pulmonx's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pulmonx (LUNG), the current Days Payable is 74.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulmonx (LUNG) Overvalued in 2026?
Based on GuruFocus' analysis, Pulmonx stock appears to be undervalued.
The current stock price of $1.30 is trading 81.8% below its estimated GF Value™ of $7.13.
GuruFocus considers Pulmonx to be Possible Value Trap.
Key valuation signals for LUNG:
Days Payable: 74.12 (41% above median its 10-year median of 52.50)
GF Value™: $7.13 vs. price of $1.30 (81.8% below fair value)
Industry Position: 8.9% above the Medical Devices & Instruments median (#332 of 795)
No single metric tells the full story. See the LUNG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
49GF Score
Get the complete analysis for LUNG
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUNG has been successfully added to your 
